CombinatoRx to pocket $42M in new collaboration

CombinatoRx has signed a deal with Angiotech Pharmaceuticals worth $42 million at closing. Boston-based CombinatoRx will gain $27 million up front and a $15 million equity investment to join a collaboration to develop new drug-device combinations and local interventional medicines. CombinatoRx has been involved in searching for new combination drugs. The intellectual property created in the collaboration will be jointly owned.

- read this press release for more information

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.